BDMD BDMD
Company Profile ↓Company Overview
BDMD (BDMD) is a publicly traded company listed on with a market capitalization of $43.85M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 1.9.
Recent Developments
- Dec 2025 Revenue of $22.54M (-39.2% YoY); net profit $-27.28M.
- Trailing 12 Months Year-on-year growth — revenue -39.1%, earnings -319.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -13.7%, profit CAGR -105.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -13.72% |
| 1 Year: | -39.15% |
Compounded Profit Growth
| 5 Years: | -105.68% |
| 1 Year: | -319.04% |
Stock Price Performance
| 1 Year: | -47.80% |
| 6 Months: | +7.00% |
| 3 Months: | -41.21% |
| 1 Month: | -9.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -13.7% CAGR over 5 years.
- Earnings shrank at -105.7% CAGR over 5 years.
- Trading 68.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 35.09M | 31.46M | 37.04M | 22.54M |
| Cost of Revenue | - | 7.05M | 4.23M | 4.38M | 3.65M |
| Gross Profit | - | 28.04M | 27.23M | 32.65M | 18.88M |
| Operating Expenses | - | 13.03M | 14.58M | 17.34M | 44.42M |
| Operating Income | - | 15.01M | 12.65M | 15.32M | -25.54M |
| EBITDA | - | 16.29M | 13.66M | 15.80M | -24.53M |
| Interest Expense | - | 299.27K | 284.27K | 576.36K | 737.37K |
| Pretax Income | - | 14.52M | 12.36M | 14.09M | -26.37M |
| Tax Provision | - | 1.75M | 1.70M | 1.49M | 1.17M |
| Net Income | - | 12.57M | 10.55M | 12.45M | -27.28M |
| Diluted EPS | 0.39 | 0.49 | 0.41 | 0.57 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 42.62M | 56.71M | 77.96M | 69.70M |
| Current Assets | - | 33.76M | 40.08M | 61.42M | 54.97M |
| Cash & Equivalents | - | 1.71M | 1.51M | 2.97M | 178.32K |
| Inventory | - | 1.29M | 1.14M | 1.30M | 1.09M |
| Receivables | - | 24.37M | 31.10M | 46.58M | 42.53M |
| Total Liabilities | - | 16.84M | 21.00M | 38.20M | 38.48M |
| Current Liabilities | - | 16.02M | 18.98M | 34.62M | 32.36M |
| Long Term Debt | - | - | 1.61M | 3.44M | 6.09M |
| Total Debt | - | 7.44M | 11.51M | 20.88M | 19.30M |
| Total Equity | - | 25.93M | 35.75M | 39.66M | 31.37M |
| Shares Outstanding | - | 35.45M | 25.56M | 35.73M | 40.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 485.97K | -1.02M | -6.31M | -1.34M |
| Investing Cash Flow | - | -5.92M | -2.65M | -2.47M | -42.31K |
| Financing Cash Flow | - | 4.41M | 3.48M | 10.33M | -1.39M |
| Capital Expenditure | - | -5.95M | -2.64M | -2.85M | -42.31K |
| Free Cash Flow | - | -5.47M | -3.66M | -9.17M | -1.39M |
| Net Change in Cash | - | -1.02M | -197.33K | 1.55M | -2.78M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 79.9% | 86.6% | 88.2% | 83.8% |
| Operating Margin % | - | 42.8% | 40.2% | 41.4% | -113.3% |
| Net Margin % | - | 35.8% | 33.5% | 33.6% | -121.0% |
| ROE % | - | 48.5% | 29.5% | 31.4% | -87.0% |
| ROCE % | - | 56.4% | 33.5% | 35.3% | -68.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Highbridge Capital Management, LLC. | 0.31% | 125.00K | $133.75K |
| 2 | UBS Group AG | 0.17% | 67.86K | $72.61K |
| 3 | Two Sigma Investments, LP | 0.11% | 46.59K | $49.85K |
| 4 | Jane Street Group, LLC | 0.10% | 39.42K | $42.17K |
| 5 | Geode Capital Management, LLC | 0.06% | 25.44K | $27.22K |
| 6 | Morgan Stanley | 0.05% | 20.00K | $21.40K |
| 7 | National Bank of Canada/FI/ | 0.03% | 11.70K | $12.52K |
| 8 | Wolverine Asset Management, LLC | - | 205 | $219 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BDMD
Baird Medical Announces First Microwave Ablation Procedures Using Its Technology in Vietnam and Argentina
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of the first procedures using its…
Baird Medical Establishes Global Headquarters in New York City, Reinforcing Commitment to U.S. Commercial Expansion
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the relocation of its global headquarters to the U.S., with…
Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate Update
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its financial results for the full year ended December 31, …
Baird Medical Advances Clinical Education with Expert-Led Workshops in Indonesia
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful execution of two clinical training workshops…
Baird Medical Expands Global Reach with Regulatory Clearance in Argentina
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the regulatory clearance of its systems in Argentina. This …
Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology at NASIT 2026
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful strategic showcase at the 2026 North America…
BDMD — Frequently Asked Questions
What is the current share price of BDMD?
As of 2026-08-05 17:25 PDT, BDMD trades at $1.07 on NASDAQ/NYSE. Its 52-week range is $0.77 to $3.44.
What is the market capitalisation of BDMD?
BDMD has a market capitalisation of $43.85M on NASDAQ/NYSE.
What is the P/E ratio of BDMD?
BDMD trades at a trailing price-to-earnings (P/E) ratio of 1.88. Its price-to-book (P/B) ratio is 1.40.
What is the return on equity (ROE) of BDMD?
BDMD has a return on equity (ROE) of -86.96%. Its return on capital employed (ROCE) is -68.66%.
Is BDMD a good stock to buy?
This page provides a data-driven analysis of BDMD, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.